文献速递类风湿关节炎

生物制剂时代类风湿关节炎经济负担的系统综述

Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.
PubMed 文献 · Ann Rheum Dis · 2020-04-03

该系统综述纳入2000至2019年72项估算RA成本的研究,评估总成本及成本构成。药物成本占直接成本主要部分(最高达87%)且呈上升趋势但无统计学意义,住院成本比例随时间显著下降(p=0.044),间接成本占总成本39%至86%,主要与缺勤和工作失能相关。

要点

  • 药物成本是直接成本主要构成,最高达87%,呈上升趋势但无统计学意义。
  • 住院成本比例随时间显著下降(p=0.044),提示直接成本内部发生转移。
  • 间接成本占总成本39%至86%,主要与缺勤和工作失能相关。

核心结论

  • 住院成本随时间下降提示直接成本其他构成发生转移。
  • 间接成本仍占总成本相当比例,工作失能是主要成本构成。
  • 未纳入或未恰当测量间接成本的经济分析将低估RA的全部经济影响。

研究设计与样本

  • 系统综述纳入2000至2019年发表的72项估算RA患者成本的研究。
  • 检索多个电子数据库,按研究和人群特征评估报告的总成本及成本构成。
  • 使用Cochran-Armitage检验判断成本比例随时间变化趋势的统计学显著性。

主要发现

  • 药物成本占直接成本主要部分,最高达87%,呈上升趋势但无统计学意义。
  • 住院成本比例随时间显著下降(p=0.044)。
  • 间接成本占总成本39%至86%,主要与缺勤和工作失能相关。
  • 报告的间接成本对估算方法高度敏感。

关键数值与推荐

  • 药物成本占直接成本最高达87%。
  • 住院成本比例随时间变化p=0.044。
  • 间接成本占总成本39%至86%。

临床怎么用

  • 评估RA经济负担时需同时纳入直接成本和间接成本。
  • 应关注药物成本上升和住院成本下降带来的成本构成变化。
  • 间接成本测量方法影响结果,需恰当测量工作失能相关成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The past decades have seen rapid advances in the treatment of rheumatoid arthritis (RA). In particular, the introduction of biologic and targeted synthetic disease-modifying antirheumatic drugs have improved clinical outcomes and reconfigured traditional RA cost compositions. OBJECTIVES: To map the existing evidence concerning cost of illness of RA, as the treatment pathway evolves in the biologic era, and examine how costs have been measured and estimated, in order to assemble and appropriately interpret available data. METHODS: Systematic review of studies that estimated the costs of patients with RA. Multiple electronic databases were searched to identify studies published between 2000 and 2019. The reported total costs and cost components were evaluated according to the study and population characteristics. The Cochran-Armitage test was used to determine statistically significant trends in increasing or decreasing proportions over time. RESULTS: Overall, 72 studies were included. Drug costs compromised the main component (up to 87%) of direct costs with an increasing trajectory over time, although not statistically significant. The proportion of costs for hospitalisation showed a statistically significant decrease chronologically (p=0.044). Indirect costs, primarily associated with absenteeism and work disability accounted for 39% to 86% of total costs. The reported indirect costs are highly sensitive to the approach to estimation. CONCLUSIONS: A decreasing trend in inpatient costs chronologically suggested a cost shift in other components of direct costs. Indirect costs still contributed a considerable proportion of total costs, with work disability being the main cost component. Economic analyses that do not incorporate or appropriately measure indirect costs will underestimate the full economic impact of RA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hsieh PH, Wu O, Geue C, et al. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis. 2020. PMID: 32245893. doi:10.1136/annrheumdis-2019-216243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。